Pharmaceutical CDMO Services

Partner with us for integrated pharmaceutical development and manufacturing - supporting oral solid dosage and DPI programs at every stage, from first-in-human clinical supply to global commercial market access.

Pharmaceutical Drug Product Development and Manufacturing for Oral and Inhalable Drug Products

Pharmaceutical CDMO Services meets Lonza Capsugel Global Pharmaceutical Solutions

Lonza Capsugel Global Pharmaceutical Solutions is a global development and manufacturing network combining specialized capsule formulation development (Innovaform® Accelerator) with end to end CDMO Pharmaceutical services for oral solid dosage forms, including tablets and capsules and Dry Powder Inhalation (DPI) drug products. We support programs from custom capsule design and early drug development through first-in-human clinical supply, cGMP manufacturing and packaging, regulatory compliance and commercial market access, with entry points at every stage of the product lifecycle.

Service Offerings

Tablets and capsules
DPI capsules
Preclinical to commercial
Regulatory compliant
DEA Schedule I to V

Why partners choose our network

The drug development and manufacturing challenges biotech and pharmaceutical companies most commonly bring to us:

Challenge	How we solve it
Need to get to clinic fast	First-in-human quick-to-clinic option: cGMP drug product from drug substance with minimal formulation development.
Too many vendors across the lifecycle	One network: formulation development through cGMP manufacturing, QC, packaging and regulatory.
Regulatory compliance across markets	FDA, MHRA, ANVISA and beyond. 5 FDA inspections. 12 non-US market audits.
Current CDMO has no proven path from concept to commercial	9 products approved. 6 currently being produced for the US and international markets.

Our approach

Bringing a drug product to market shouldn't mean navigating unnecessary complexity. Fragmented outsourcing can slow progress, introduce risk, and dilute critical know how. Our model is designed differently. A single pharmaceutical development partner supports your drug product from early formulation through commercial readiness, bringing scientific, operational, and regulatory expertise together within one connected ecosystem.

Our integrated network is supported by experienced teams with deep capabilities spanning pre‑clinical development through commercialization, across both oral solid dosage and inhaled drug products. The same formulation, analytical, and regulatory insight that shapes your product early on remains with it as you scale enabling efficient technology transfer, consistent project execution, and a smoother path to market access.

Therapeutic areas

Our drug development and manufacturing services support biotech and pharma programs across:

Oncology and HPAPIs

Respiratory and inhalation

CNS

Metabolic and chronic diseases

Oral peptides

Rare diseases

Not sure which site fits your program?

Tell us where you are in development and we will point you in the right direction. Contact us here.

Our network

Two complementary specialized sites combining formulation development expertise and CDMO manufacturing capabilities, operating as one seamless pharmaceutical outsourcing partner.

Innovaform® Accelerator

Colmar, France

Our European center for solving drug delivery challenges through custom capsule design and early-stage formulation development. Specializing in oral solid, lipid-based liquid fill, and DPI capsule formulations. Programs generated at Innovaform® Accelerator are developed and documented to support potential transfer to the Tampa site.

Custom capsule design | Lipid-based formulations | DPI development | POC to GMP transfer

Explore →

CDMO Services – US Site

Tampa, United States

Our US-based CDMO for full-lifecycle oral solid dosage and DPI drug product services. From first-in-human clinical supply and GMP manufacturing through QC testing, packaging, stability, and regulatory affairs. DEA Schedule I to V licensed. Nine products approved from this site, six currently on market.

FDA inspected | DEA Schedule I to V | HPAPI capable | FIH to commercial

Explore →